There was also a significant increase in the frequency of MDSCs in HCC patients compared to healthy controls when MDSCs were identified as “HLA-DRlow/-CD14+” (SMD = 5.55, 95% CI = 1.67–9.43, P = 0.005). Here, CD14 is linked to hepatocellular carcinoma.